{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T19:55:16Z","timestamp":1794254116676,"version":"4.9.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006739","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2008,4,23]],"date-time":"2008-04-23T00:00:00Z","timestamp":1208908800000}}],"reference-count":104,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006739.pub2","type":"journal-article","created":{"date-parts":[[2008,4,21]],"date-time":"2008-04-21T05:56:47Z","timestamp":1208757407000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus"],"prefix":"10.1002","volume":"2010","author":[{"given":"Bernd","family":"Richter","sequence":"first","affiliation":[{"name":"Universitaetsklinikum Duesseldorf, Heinrich-Heine University; Department of General Practice; PO Box 101007 Duesseldorf Germany 40001"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Bandeira-Echtler","sequence":"additional","affiliation":[{"name":"Universitaetsklinikum Duesseldorf, Heinrich-Heine University; Department of General Practice; PO Box 101007 Duesseldorf Germany 40001"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Bergerhoff","sequence":"additional","affiliation":[{"name":"Universitaetsklinikum Duesseldorf, Heinrich-Heine University; Department of General Practice; PO Box 101007 Duesseldorf Germany 40001"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lerch","sequence":"additional","affiliation":[{"name":"Universitaetsklinikum Duesseldorf, Heinrich-Heine University; Department of General Practice; PO Box 101007 Duesseldorf Germany 40001"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,4,23]]},"reference":[{"issue":"12","key":"10.1002\/14651858.CD006739.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.2337\/diacare.27.12.2874","article-title":"Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes","volume":"27","author":"Ahren","year":"2004","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1002\/14651858.CD006739.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.2337\/dc06-0703","article-title":"Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes","volume":"29","author":"Aschner","year":"2006","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD006739.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1463-1326.2007.00820.x","article-title":"Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study","volume":"10","author":"Bolli","year":"2008","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD006739.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"890","DOI":"10.2337\/dc06-1732","article-title":"Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin","volume":"30","author":"Bosi","year":"2007","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1002\/14651858.CD006739.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.2337\/dc06-0706","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone","volume":"29","author":"Charbonnel","year":"2006","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD006739.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1055\/s-2007-970422","article-title":"Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study","volume":"39","author":"Dejager","year":"2007","journal-title":"Hormone & Metabolic Research"},{"issue":"6","key":"10.1002\/14651858.CD006739.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1007\/s00125-007-0633-0","article-title":"Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes","volume":"50","author":"Fonseca","year":"2007","journal-title":"Diabetologia"},{"issue":"2","key":"10.1002\/14651858.CD006739.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1463-1326.2006.00684.x","article-title":"Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study","volume":"9","author":"Garber","year":"2007","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"8","key":"10.1002\/14651858.CD006739.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.2337\/dc07-0627","article-title":"Effect of Initial Combination Therapy with Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients with Type 2 Diabetes","volume":"30","author":"Goldstein","year":"2007","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1002\/14651858.CD006739.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1185\/030079907X188152","article-title":"Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes","volume":"23","author":"Hanefeld","year":"2007","journal-title":"Current Medical Research & Opinion"},{"issue":"5","key":"10.1002\/14651858.CD006739.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1463-1326.2007.00744.x","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin","volume":"9","author":"Hermansen","year":"2007","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1002\/14651858.CD006739.pub2-BIB0012|cit12","first-page":"A125","article-title":"Vildagliptin improves glucose control as evidenced by HbA1c after 12 weeks in Japanese patients with type 2 diabetes","volume":"55(suppl 1)","author":"Mimori","year":"2006","journal-title":"Diabetes"},{"issue":"2","key":"10.1002\/14651858.CD006739.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1463-1326.2006.00704.x","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial","volume":"9","author":"Nauck","year":"2007","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD006739.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.diabres.2007.08.021","article-title":"Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes","volume":"79","author":"Nonaka","year":"2008","journal-title":"Diabetes Research and Clinical Practice"},{"key":"10.1002\/14651858.CD006739.pub2-BIB0015|cit15","first-page":"A129","article-title":"Twelve-week efficacy and tolerability of sitagliptin, a dipeptidyl peptidase-IV inhibitor, in Japanese patients with T2DM","volume":"55(suppl 1)","author":"Nonaka","year":"2006","journal-title":"Diabetes"},{"issue":"1","key":"10.1002\/14651858.CD006739.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.diabres.2006.12.009","article-title":"Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes","volume":"76","author":"Pi-Sunyer","year":"2007","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"6","key":"10.1002\/14651858.CD006739.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1055\/s-2006-944546","article-title":"Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes","volume":"38","author":"Pratley","year":"2006","journal-title":"Hormone & Metabolic Research"},{"issue":"11","key":"10.1002\/14651858.CD006739.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1007\/s00125-006-0416-z","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus","volume":"49","author":"Raz","year":"2006","journal-title":"Diabetologia"},{"issue":"6","key":"10.1002\/14651858.CD006739.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1463-1326.2005.00539.x","article-title":"Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response","volume":"7","author":"Ristic","year":"2005","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"10","key":"10.1002\/14651858.CD006739.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.clinthera.2006.10.007","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"28","author":"Rosenstock","year":"2006","journal-title":"Clinical Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD006739.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2337\/dc06-1815","article-title":"Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial","volume":"30","author":"Rosenstock","year":"2007","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD006739.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1463-1326.2006.00698.x","article-title":"Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes","volume":"9","author":"Rosenstock","year":"2007","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD006739.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1210\/jc.2007-1639","article-title":"Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia","volume":"93","author":"Mari","year":"2008","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"8","key":"10.1002\/14651858.CD006739.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1463-1326.2008.00850.x","article-title":"Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia","volume":"10","author":"Scherbaum","year":"2008","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"9","key":"10.1002\/14651858.CD006739.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1464-5491.2007.02191.x","article-title":"Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetes","volume":"24","author":"Schweizer","year":"2007","journal-title":"Diabetic Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006739.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1742-1241.2006.01246.x","article-title":"Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes","volume":"61","author":"Scott","year":"2007","journal-title":"International Journal of Clinical Practice"},{"issue":"10","key":"10.1002\/14651858.CD006739.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/j.1463-1326.2007.00839.x","article-title":"Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes","volume":"10","author":"Scott","year":"2007","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1002\/14651858.CD006739.pub2-BIB0028|cit28","first-page":"S5","article-title":"Report on the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus","volume":"20 Suppl 1","author":"American Diabetes Association","year":"1997","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD006739.pub2-BIB0029|cit29","first-page":"S5","article-title":"Report of the Expert Committee on the diagnosis and classification of diabetes mellitus","volume":"22 Suppl 1","author":"The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus","year":"1999","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1002\/14651858.CD006739.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11892-003-0079-9","article-title":"Gut peptides and type 2 diabetes mellitus treatment. [Review] [50 refs]","volume":"3","author":"Ahren","year":"2003","journal-title":"Current Diabetes Reports"},{"issue":"4","key":"10.1002\/14651858.CD006739.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1517\/13543784.15.4.431","article-title":"Vildagliptin: An inhibitor of dipeptidyl peptidase-4 with antidiabetic properties","volume":"15","author":"Ahren","year":"2006","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"6","key":"10.1002\/14651858.CD006739.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.2337\/dc07-0233","article-title":"Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications","volume":"30","author":"Ahren","year":"2007","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD006739.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.298.2.194","article-title":"Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis","volume":"298","author":"Amori","year":"2007","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD006739.pub2-BIB0034|cit34","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004656","article-title":"Initiating and maintaining physical activity for type 2 diabetes mellitus","author":"Armour","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD006739.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/j.1742-1241.2006.01178.x","article-title":"DPP-4 inhibitors and their potential role in the management of type 2 diabetes","volume":"60","author":"Barnett","year":"2006","journal-title":"International Journal of Clinical Practice"},{"issue":"4","key":"10.1002\/14651858.CD006739.pub2-BIB0036|cit36","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004654.pub2","article-title":"Meglitinide analogues for type 2 diabetes mellitus","author":"Black","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD006739.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1345\/aph.1H459","article-title":"Rationale for dipeptidyl peptidase 4 inhibitors: A new class of oral agents for the treatment of type 2 diabetes mellitus","volume":"41","author":"Campbell","year":"2007","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD006739.pub2-BIB0038|cit38","article-title":"Vildagliptin (Structured abstract)","author":"Canadian Agency for Drugs and Technologies in Health","year":"2006","journal-title":"Ottawa : Canadian Agency for Drugs and Technologies in Health"},{"key":"10.1002\/14651858.CD006739.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/001316446002000104","article-title":"A coefficient of agreement for nominal scales","volume":"20","author":"Cohen","year":"1960","journal-title":"Educational and Psychological Measurement"},{"issue":"14","key":"10.1002\/14651858.CD006739.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"The diabetes control and complications trial research group","year":"1993","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006739.pub2-BIB0041|cit41","first-page":"419","article-title":"MK-431 (Merck)","volume":"6","author":"Deacon","year":"2005","journal-title":"Current Opinion in Investigational Drugs"},{"key":"10.1002\/14651858.CD006739.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2337\/diacare.15.3.318","article-title":"Pathogenesis of NIDDM: a balanced overview","volume":"15","author":"DeFronzo","year":"1992","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD006739.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD006739.pub2-BIB0044|cit44","first-page":"109","article-title":"Sitagliptin","volume":"Drug Discovery.","author":"Drucker","year":"2007","journal-title":"Nature Reviews"},{"issue":"7317","key":"10.1002\/14651858.CD006739.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/bmj.323.7317.854","article-title":"The case against aggressive treatment of type 2 diabetes: critique of the UK prospective diabetes study","volume":"323","author":"Ewart","year":"2001","journal-title":"BMJ"},{"issue":"19","key":"10.1002\/14651858.CD006739.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1001\/jama.289.19.2554","article-title":"Composite outcomes in randomized trials: greater precision but with greater uncertainty?","volume":"289","author":"Freemantle","year":"2003","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD006739.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1358\/dot.2007.43.1.1043909","article-title":"Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes","volume":"43","author":"Gallwitz","year":"2007","journal-title":"Drugs of Today"},{"issue":"1","key":"10.1002\/14651858.CD006739.pub2-BIB0048|cit48","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003054","article-title":"Lifestyle interventions for preventing type 2 diabetes mellitus","author":"Gimenez-Perez","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD006739.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3132\/dvdr.2006.024","article-title":"Dipeptidyl peptidas IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes","volume":"3","author":"Green","year":"2006","journal-title":"Diabetes and Vascular Disease Research"},{"key":"10.1002\/14651858.CD006739.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction","volume":"339","author":"Haffner","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006739.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00004872-199303000-00012","article-title":"Hypertension in diabetes study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications","volume":"11","author":"The Hypertension in Diabetes Study Group","year":"1993","journal-title":"Journal of Hypertension"},{"issue":"15","key":"10.1002\/14651858.CD006739.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.2165\/00003495-200666150-00007","article-title":"Vildagliptin","volume":"66","author":"Henness","year":"2006","journal-title":"Drugs"},{"issue":"5","key":"10.1002\/14651858.CD006739.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/sj.clpt.6100167","article-title":"Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: Focus on sitagliptin","volume":"81","author":"Herman","year":"2007","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD006739.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in medicine"},{"key":"10.1002\/14651858.CD006739.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analysis","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006739.pub2-BIB0056|cit56","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005] In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd"},{"issue":"2","key":"10.1002\/14651858.CD006739.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1463-1326.2007.00705.x","article-title":"Dipeptidyl peptidase-IV inhibitors: A major new class of oral antidiabetic drug","volume":"9","author":"Idris","year":"2007","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1002\/14651858.CD006739.pub2-BIB0058|cit58","article-title":"The pathophysiology of type II (noninsulindependent) diabetes mellitus: implications for treatment","volume-title":"Ellenberg & Rifkin's Diabetes Mellitus","author":"Kahn","year":"1997"},{"issue":"5","key":"10.1002\/14651858.CD006739.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1345\/aph.1H460","article-title":"The role of vildagliptin in the management of type 2 diabetes mellitus. [Review] [29 refs]","volume":"41","author":"Kleppinger","year":"2007","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD006739.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2337\/diabetes.48.5.937","article-title":"Hyperglycemia and cardiovascular disease in type 2 diabetes","volume":"48","author":"Laakso","year":"1999","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD006739.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1136\/bmj.333.7568.597","article-title":"The case of the misleading funnel plot","volume":"333","author":"Lau","year":"2006","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD006739.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1185\/030079907X178766","article-title":"Oral antidiabetic agents in type 2 diabetes","volume":"23","author":"Levetan","year":"2007","journal-title":"Current Medical Research & Opinion"},{"issue":"4","key":"10.1002\/14651858.CD006739.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2165\/00003495-200767040-00007","article-title":"Sitagliptin","volume":"67","author":"Lyseng-Williamson","year":"2007","journal-title":"Drugs"},{"issue":"1","key":"10.1002\/14651858.CD006739.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1210\/jc.2004-0699","article-title":"Sulfonylurea induced beta-cell apoptosis in cultured human islets","volume":"90","author":"Maedler","year":"2005","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD006739.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/archinte.1991.00400060077013","article-title":"A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women","volume":"151","author":"Manson","year":"1991","journal-title":"Archives of Internal Medicine"},{"issue":"19","key":"10.1002\/14651858.CD006739.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1001\/jama.289.19.2545","article-title":"Analysis and reporting of factorial trials: a systematic review","volume":"289","author":"McAlister","year":"2003","journal-title":"JAMA"},{"issue":"7251","key":"10.1002\/14651858.CD006739.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1136\/bmj.320.7251.1720","article-title":"Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. United Kingdom prospective diabetes study","volume":"320","author":"McCormack","year":"2000","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD006739.pub2-BIB0068|cit68","first-page":"338","article-title":"Dipeptidyl peptidase-IV inhibitors can restore glucose homeostasis in type 2 diabetics via incretin enhancement","volume":"7","author":"Mest","year":"2006","journal-title":"Current Opinion in Investigational Drugs"},{"issue":"7-8","key":"10.1002\/14651858.CD006739.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1345\/aph.1G665","article-title":"Sitagliptin: A dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes","volume":"40","author":"Miller","year":"2006","journal-title":"Annals of Pharmacotherapy"},{"issue":"1","key":"10.1002\/14651858.CD006739.pub2-BIB0070|cit70","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005103","article-title":"Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus","author":"Misso","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9193","key":"10.1002\/14651858.CD006739.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","article-title":"Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses","volume":"354","author":"Moher","year":"1999","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006739.pub2-BIB0072|cit72","first-page":"26","article-title":"Design, analysis and presentation of factorial randomised controlled trials","volume":"3","author":"Montgomery","year":"2003","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD006739.pub2-BIB0073|cit73","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004097.pub4","article-title":"Dietary advice for the prevention of type 2 diabetes mellitus in adults","author":"Moore","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9131","key":"10.1002\/14651858.CD006739.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0140-6736(98)22937-0","article-title":"Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study","volume":"352","author":"Nathan","year":"1998","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006739.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0168-8227(95)01064-K","article-title":"Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent mellitus: a randomized prospective 6-year study","volume":"28","author":"Ohkubo","year":"1995","journal-title":"Diabetes Research and Clinical Practice"},{"issue":"4","key":"10.1002\/14651858.CD006739.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1185\/030079906X162746","article-title":"Inhibition of DPP-4: A new therapeutic approach for the treatment of type 2 diabetes","volume":"23","author":"Pratley","year":"2007","journal-title":"Current Medical Research & Opinion"},{"issue":"1","key":"10.1002\/14651858.CD006739.pub2-BIB0077|cit77","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003816.pub2","article-title":"'Human' insulin versus animal insulin in people with diabetes mellitus","author":"Richter","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD006739.pub2-BIB0078|cit78","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006060.pub2","article-title":"Pioglitazone for type 2 diabetes mellitus","author":"Richter","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD006739.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1358\/dot.2006.42.8.996570","article-title":"Vildagliptin: A novel DPP-4 inhibitor with pancreatic islet enhancement activity for treatment of patients with type 2 diabetes","volume":"42","author":"Ristic","year":"2006","journal-title":"Drugs of Today"},{"issue":"2","key":"10.1002\/14651858.CD006739.pub2-BIB0080|cit80","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005271","article-title":"Glargine versus other basal insulins (NPH, Lente, or Ultralente) for the treatment of type 1 diabetes mellitus","author":"Roberts","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD006739.pub2-BIB0081|cit81","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003890.pub3","article-title":"Inhaled insulin in diabetes mellitus","author":"Royle","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006739.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"491\u20136","DOI":"10.2337\/diacare.20.4.491","article-title":"Performance of an NIDDM screening questionnaire based on symptoms and risk factors","volume":"20","author":"Ruige","year":"1997","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD006739.pub2-BIB0083|cit83","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002966.pub3","article-title":"Metformin monotherapy for type 2 diabetes mellitus","author":"Saenz","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD006739.pub2-BIB0084|cit84","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002967.pub2","article-title":"Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus","author":"Salpeter","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD006739.pub2-BIB0085|cit85","first-page":"494","article-title":"Vildagliptin: A dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes","volume":"41","author":"Schlesselman","year":"2006","journal-title":"Formulary"},{"issue":"6","key":"10.1002\/14651858.CD006739.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2174\/156802607780091019","article-title":"Dipeptidyl peptidase IV inhibitors: The next generation of new promising therapies for the management of type 2 diabetes","volume":"7","author":"Sebokova","year":"2007","journal-title":"Current Topics in Medicinal Chemistry"},{"issue":"4","key":"10.1002\/14651858.CD006739.pub2-BIB0087|cit87","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003287.pub4","article-title":"Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus","author":"Siebenhofer","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD006739.pub2-BIB0088|cit88","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006423","article-title":"Glucagon-like peptide analogues for type 2 diabetes mellitus","author":"Snaith","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006739.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/diacare.16.2.434","article-title":"Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the multiple risk factor intervention trial","volume":"16","author":"Stamler","year":"1993","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD006739.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/9780470693926.ch11","article-title":"Investigating and dealing with publication and other biases","volume-title":"Systematic Reviews in Health Care; Meta-analysis in Context","author":"Sterne","year":"2001"},{"issue":"7258","key":"10.1002\/14651858.CD006739.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD006739.pub2-BIB0092|cit92","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002968.pub2","article-title":"Exercise for type 2 diabetes mellitus","author":"Thomas","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD006739.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2174\/156802607780091028","article-title":"Discovery of JANUVIA (sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type2 diabetes","volume":"7","author":"Thornberry","year":"2007","journal-title":"Current Topics in Medicinal Chemistry"},{"issue":"3","key":"10.1002\/14651858.CD006739.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1464-5491.2006.02071.x","article-title":"Incretins and other peptides in the treatment of diabetes","volume":"24","author":"Todd","year":"2007","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD006739.pub2-BIB0095|cit95","first-page":"1","article-title":"Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes, VIII. Evaluation of insulin therapy: final report","volume":"31 Suppl 5","author":"University Group Diabetes Program","year":"1982","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD006739.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2337\/diab.44.11.1249","article-title":"U.K. prospective diabetes study 16: overview of 6 years' therapy of type II diabetes: a progressive disease","volume":"44","author":"U.K. Prospective Diabetes Study Group","year":"1995","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD006739.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes-UKPDS 33","volume":"352","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006739.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes","volume":"352","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"Lancet"},{"issue":"7160","key":"10.1002\/14651858.CD006739.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD006739.pub2-BIB0100|cit100","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003639.pub2","article-title":"Alpha-glucosidase inhibitors for type 2 diabetes mellitus","author":"Laar","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006739.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"909\u201315","DOI":"10.7326\/0003-4819-113-12-909","article-title":"Slow glucose removal rate and hyperinsulinemia precede the development of Type 2 diabetes in the offspring of diabetic parents","volume":"113","author":"Warram","year":"1990","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD006739.pub2-BIB0102|cit102","unstructured":"WHO Expert Committee on Diabetes Mellitus Second report. Technical Report Series 646 Geneva. WHO, 1980"},{"key":"10.1002\/14651858.CD006739.pub2-BIB0103|cit103","unstructured":"WHO Expert Committee on Diabetes Mellitus World Health Organization, 1985. Technical Report Series 727"},{"key":"10.1002\/14651858.CD006739.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its compliactions. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabetic Medicine"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD006739.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:17:50Z","timestamp":1762874270000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006739.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Metabolic and Endocrine Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2008,4,23]]},"references-count":104,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006739.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,23]]}}}